Contrasting Positron (POSC) and Its Competitors

Positron (OTCMKTS:POSC) is one of 71 publicly-traded companies in the “Electromedical equipment” industry, but how does it weigh in compared to its peers? We will compare Positron to related companies based on the strength of its valuation, earnings, analyst recommendations, institutional ownership, risk, dividends and profitability.

Insider & Institutional Ownership

44.7% of shares of all “Electromedical equipment” companies are owned by institutional investors. 17.2% of Positron shares are owned by insiders. Comparatively, 13.2% of shares of all “Electromedical equipment” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Positron and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Positron	$740,000.00	-$1.64 million	-11.75
Positron Competitors	$1.06 billion	$88.76 million	-8.38

Positron’s peers have higher revenue and earnings than Positron. Positron is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of recent recommendations for Positron and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Positron	0	0	0	0	N/A
Positron Competitors	266	798	1967	59	2.59

As a group, “Electromedical equipment” companies have a potential upside of 3,107.40%. Given Positron’s peers higher probable upside, analysts plainly believe Positron has less favorable growth aspects than its peers.

Profitability

This table compares Positron and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Positron	-300.00%	N/A	-89.57%
Positron Competitors	-341.23%	-95.28%	-31.21%

Volatility & Risk

Positron has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500. Comparatively, Positron’s peers have a beta of 1.02, suggesting that their average stock price is 2% more volatile than the S&P 500.

Summary

Positron peers beat Positron on 7 of the 10 factors compared.

Positron Company Profile

Positron Corporation, a nuclear medicine healthcare company, specializes in the business of cardiac positron emission tomography (PET) imaging in the United States. It offers attrius PET scanner, clinical and technical services, and financing solutions enables healthcare providers to accurately diagnose cardiac disease, improve patient outcomes, and practice cost effective medicines. Positron Corporation was incorporated in 1983 and is based in Niagara Falls, New York.